We are live on ! Find out more
ONCY

Oncolytics Biotech
ONCY

36 hedge funds and large institutions have $822K invested in Oncolytics Biotech in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 2

17% more capital invested

Capital invested by funds: $700K → $822K (+$121K)

0.36% less ownership

Funds ownership: 1.59% → 1.23% (-0.36%)

14% less funds holding

Funds holding: 42 → 36 (-6)

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

Holders
36
Holders Change
-6
Holders Change %
-14.29%
% of All Funds
0.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
9
Reduced
2
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NDSI
Newman Dignan & Sheerar Inc
Rhode Island
+$15.8K
2
Renaissance Technologies
Renaissance Technologies
New York
+$13K
3
Morgan Stanley
Morgan Stanley
New York
+$8.07K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$6.31K
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$5.07K

Top Sellers

Rank Fund Capital Flow
1
ARC
Advisor Resource Council
Texas
-$101K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$70K
3
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
-$34K
4
TSS
Two Sigma Securities
New York
-$21K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$11K
Name Holding Trade Value Shares
Change 		Change in
Stake
IAIM
1
International Assets Investment Management
Florida
$223K +$1.53K +1,250 +0.7%
Morgan Stanley
2
Morgan Stanley
New York
$121K +$8.07K +6,587 +7%
CIBC World Market
3
CIBC World Market
Ontario, Canada
$77K +$15 +12 +0%
Royal Bank of Canada
4
Royal Bank of Canada
Ontario, Canada
$60K +$6.31K +5,153 +12%
LFCM
5
Long Focus Capital Management
Puerto Rico
$49K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$42K – – –
Dimensional Fund Advisors
7
Dimensional Fund Advisors
Texas
$41K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$30K +$13K +10,600 +76%
BAM
9
Brave Asset Management
New Jersey
$25K – – –
Comerica Bank
10
Comerica Bank
Texas
$20K – – –
LPL Financial
11
LPL Financial
California
$20K – – –
Stifel Financial
12
Stifel Financial
Missouri
$20K +$3.97K +3,243 +26%
BCV
13
Banque Cantonale Vaudoise
Switzerland
$15K – – –
Osaic Holdings
14
Osaic Holdings
Arizona
$10K – – –
FDCDDQ
15
Federation des caisses Desjardins du Quebec
Quebec, Canada
$9.81K +$4.9K +4,000 +102%
UBS Group
16
UBS Group
Switzerland
$9K -$3.13K -2,558 -25%
CMA
17
Cedar Mountain Advisors
Oregon
$7K – – –
DI
18
Disciplined Investments
Oklahoma
$6K – – –
Rockefeller Capital Management
19
Rockefeller Capital Management
New York
$6K – – –
TCOV
20
Trust Company of Vermont
Vermont
$6K – – –
TRCT
21
Tower Research Capital (TRC)
New York
$5K -$2.95K -2,409 -39%
Wells Fargo
22
Wells Fargo
California
$5K – – –
National Bank of Canada
23
National Bank of Canada
Quebec, Canada
$4K – – –
Bank of America
24
Bank of America
North Carolina
$4K +$437 +357 +11%
SAM
25
Strategic Asset Management
Minnesota
$3K – – –
1
2

ONCY Hedge Fund Activity: Q3 2022 in Review

36 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q3 2022, worth a combined $822K — up 17% from $700K a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of ONCY and 2 opened new positions — a net loss of 6 holders — while 2 trimmed existing stakes and 9 added.

The largest buyer was Newman Dignan & Sheerar Inc, opening a new position worth an estimated $15.8K. The largest seller was Advisor Resource Council, exiting entirely with an estimated $101K sold.

  • 36 institutional investors held Oncolytics Biotech (ONCY) as of Q3 2022, down from 42 in Q2 2022.
  • Funds reported $822K of Oncolytics Biotech stock for Q3 2022, up 17% quarter-over-quarter.
  • 2 funds opened new Oncolytics Biotech positions in Q3 2022 and 8 closed out, a net change of -6 holders.
  • The largest Oncolytics Biotech buyer in Q3 2022 was Newman Dignan & Sheerar Inc, an estimated $15.8K added.
  • The largest Oncolytics Biotech seller in Q3 2022 was Advisor Resource Council, an estimated $101K sold.

Based on aggregated 13F filings for Q3 2022.